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Abstract
Background: The pulmonary residence time of inhaled glucocorticoids as well as their rate and
extend of absorption into systemic circulation are important facets of their efficacy-safety profile.
We evaluated a novel approach to elucidate the pulmonary absorption of an inhaled glucocorticoid.
Our objective was to monitor and compare the combined process of drug particle dissolution, pro-
drug activation and time course of initial distribution from human lung tissue into plasma for two
different glucocorticoid formulations.
Methods: We chose beclomethasone dipropionate (BDP) delivered by two different commercially
available HFA-propelled metered dose inhalers (Sanasthmax®/Becloforte™ and Ventolair®/
Qvar™). Initially we developed a simple dialysis model to assess the transfer of BDP and its active
metabolite from human lung homogenate into human plasma. In a novel experimental setting we
then administered the aerosols into the bronchus of an extracorporally ventilated and reperfused
human lung lobe and monitored the concentrations of BDP and its metabolites in the reperfusion
fluid.
Results:  Unexpectedly, we observed differences between the two aerosol formulations
Sanasthmax®/Becloforte™ and Ventolair®/Qvar™ in both the dialysis as well as in the human
reperfusion model. The HFA-BDP formulated as Ventolair®/Qvar™ displayed a more rapid release
from lung tissue compared to Sanasthmax®/Becloforte™. We succeeded to explain and illustrate
the observed differences between the two aerosols with their unique particle topology and
divergent dissolution behaviour in human bronchial fluid.
Conclusion: We conclude that though the ultrafine particles of Ventolair®/Qvar™ are beneficial
for high lung deposition, they also yield a less desired more rapid systemic drug delivery. While the
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differences between Sanasthmax®/Becloforte™ and Ventolair®/Qvar™ were obvious in both the
dialysis and lung perfusion experiments, the latter allowed to record time courses of pro-drug
activation and distribution that were more consistent with results of comparable clinical trials.
Thus, the extracorporally reperfused and ventilated human lung is a highly valuable physiological
model to explore the lung pharmacokinetics of inhaled drugs.
Introduction
Current asthma management guidelines recommend
inhaled glucocorticoids as preferred therapy for control of
mild persistent, moderate and severe asthma [1,2]. Gluco-
corticoids are the most effective anti-inflammatory agents
and inhalation is an efficient way to deposit the com-
pound in the therapeutic target tissue. The dose and the
percentage of lung deposition as well as the specific recep-
tor binding affinity determine the therapeutic efficacy of
the corticosteroid [3,4]. Prolonged residence of an inhaled
glucocorticoid in the lung tissue is associated with an
extended duration of action. In contrast, the rate and
extend of absorption of the glucocorticoid into systemic
circulation might result in systemic adverse effects such as
adrenal suppression or decreased bone mineral density
[5]. Though the tissue residence time and the time course
of distribution into systemic circulation significantly con-
tribute to the risk-benefit value of inhaled corticosteroids
[4,6] the precise determination of the pulmonary absorp-
tion is a challenge.
The time course of inhaled drug absorption has been fre-
quently studied in life animals [7]. For this purpose, the
drugs are usually administered intratracheally as solution
or via intratracheal nebulization [8]. This, however, is not
directly comparable to the administration of therapeuti-
cally used glucocorticoids in humans which are usually
formulated as aerosols or dry powder inhalers containing
micronized drug crystals.
The  in vivo distribution of inhaled glucocorticoids
between human lung tissue and plasma has been deter-
mined in patients undergoing thoracotomy. During sur-
gery tissue and plasma samples were obtained and
analyzed for drug concentrations which were found to be
significantly higher in lung tissue compared to plasma [9-
11]. The strength of this type of evaluation is that tissue
concentrations of the drug can be measured up to ten or
more hours after inhalation. However, one patient pro-
vides one data point only and thus many patients are
needed to sufficiently describe a time course of tissue –
plasma distribution.
Plasma concentrations of glucocorticoids after inhalation
of therapeutic doses are low and thus highly sensitive ana-
lytical methods are required [12]. Blood samples from an
antecubital vein are collected at defined time intervals
after inhalation and analyzed. Since an unknown percent-
age of the corticosteroid in this blood sample might have
already undergone metabolization when passing the liver,
it cannot be excluded that the measured concentration
underestimates the amount of active drug delivered from
the lung tissue.
The purpose of this study was to monitor and compare the
combined process of drug particle dissolution, pro-drug
activation and time course of distribution from human
lung tissue into plasma in the absence of hepatic metabo-
lism. We chose beclomethasone dipropionate (BDP) as a
model compound because different formulations are
commercially available and pharmacokinetic data from
clinical studies is accessible for comparison. BDP is acti-
vated in human lung tissue to yield its active metabolite
beclomethasone-17-monopropionate (17-BMP) [13]. We
initially developed a dialysis model to monitor the drug
transfer of BDP and metabolites from human lung tissue
homogenate into human plasma. To compare the results
of these experiments with a more physiological model we
studied drug diffusion kinetics employing resected intact
human lung lobes. This human lung reperfusion model
was previously developed by Linder et al. [14] and suc-
cessfully used to study the uptake kinetics of anticancer
agents from the perfusion fluid into normal and tumour
lung tissue [15,16]. To our knowledge, human lung reper-
fusion settings have not been employed so far for evalua-
tion of distribution kinetics of inhaled drugs. Thus, we
used the human reperfusion model in a novel experimen-
tal context. The ventilated lung lobe offered the unique
potential to administer the BDP formulation from a com-
mercially available aerosol directly into the bronchus. The
concentration of BDP and its metabolites could be then
monitored by analyzing samples from the main venous
vessel.
Materials and Methods
Chemicals, reagents and drug preparations
Beclomethasone dipropionate (BDP) pressurized metered
dose inhalers (MDI) with hydrofluorocarbon (HFA) pro-
pellant (Sanasthmax®/Becloforte™ 250 µg/dose [Asche
Chiesi GmbH, Hamburg, Germany] and Ventolair®/
Qvar™ 100 µg/dose [3 M Medica, Neuss, Germany]) or
chlorofluorocarbon (CFC) propellant (Sanasthmax®/
Becloforte™) were obtained from a local pharmacy. BDP,
beclomethasone-17-propionate (17-BMP),Respiratory Research 2005, 6:21 http://respiratory-research.com/content/6/1/21
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beclomethasone-21-propionate (21-BMP), beclometha-
sone (B) and fluticasone propionate (FP) were a generous
gift from GlaxoSmithKline (Greenford, England). Dieth-
ylether (HPLC grade) was purchased from Fluka (Buchs,
Switzerland) and acetonitrile (ACN, HPLC gradient
grade) from Fisher Scientific (Schwerte, Germany). Water
was obtained from a Millipore™ water purification unit.
Bovine serum albumin (BSA), dextrane 70000, and N-(2-
hydroxyethyl)piperazine-N'-2-ethanesulfonic acid
(HEPES) were purchased from GERBU (Heidelberg, Ger-
many), glucose monohydrate from Gruessing GmbH (Fil-
sum, Germany), and stock solution containing 10000 IU/
mL penicilline and 10000 µg/mL streptomycine in 0.9%
NaCl from Biochrom AG (Berlin, Germany). All other
chemicals were obtained from E. Merck (Darmstadt,
Germany).
Source and handling of human specimen for dialysis and 
scanning electron microscopy experiments
Human lung tissue specimen were obtained from patients
with bronchial carcinomas who gave informed consent.
Only cancer-free tissue was used for the experiments.
None of the patients was treated with glucocorticoids for
the last 4 weeks prior to surgery. Tissue samples were
shock frozen in liquid nitrogen after resection and stored
at -70°C until usage. To collect sufficient material for the
experiments, tissue samples of three or more patients were
pooled. Tissue was thawed and cut into small pieces. One
part of the tissue pieces was homogenized in two parts of
Krebs-Ringer-HEPES buffer (118 mM NaCl, 4.84 mM KCl,
1.2 mM KH2PO4, 2.43 mM MgSO4 × 6 H2O, 2.44 mM
CaCl2 × 2H2O and 10 mM HEPES; pH = 7.4). Homogeni-
zation was performed under continuous cooling using an
Ultraturrax (Janke & Kunkel, Staufen, Germany). Before
starting the series of dialysis experiments the required
amount of human lung homogenate was estimated and
subsequently a sufficient amount was prepared and
divided into aliquots. Since all aliquots descended from
this preparation protein content and enzymatic activity of
the homogenate was identical for each experiment.
Plasma samples were obtained from healthy volunteers
who gave informed consent. Samples were either used
immediately or were shock frozen in liquid nitrogen and
stored at -70°C until usage.
Bronchial fluid was collected from patients undergoing
bronchoscopy for diagnostic purposes after having
obtained informed consent. Bronchial fluid was obtained
through a sterile plastic catheter inserted into the biopsy
channel of the bronchoscope (Olympus BF 1 T 30;
München, Germany), wedged into a subsegment bron-
chus. Small bronchial fluid aliquots of four patients were
collected and pooled. The specimen was frozen and stored
at -70°C until usage.
Patients and lung preparations for perfusion experiments
Six patients with a bronchial tumour undergoing standard
thoracotomy, were included in the study. None of the
patients was treated with glucocorticoids for the last 4
weeks prior to surgery. Only patients with tumours that
were located peripherally within the lung lobe were
included. Each patient signed a written informed consent
before surgery, and a local Ethics Committee approved
the use of resected human lungs for perfusion. Immedi-
ately after perfusion, the lung preparations were examined
as usually by a pathologist.
Dialysis experiments
Dialysis was performed with a dialysis unit (designed by
our working group) consisting of two individual tightly
fitting Teflon chambers separated by a dialysis membrane
(Figure 1). One chamber (inner diameter: 45 mm, inter-
nal depth: 3 mm) was prepared for lung tissue homoge-
nate, the other chamber (inner diameter: 45 mm, internal
depth: 6 mm) was supposed to be filled with human
plasma. The chamber for plasma had two apertures for
obtaining dialysis samples and addition of fresh plasma.
In initial experiments we evaluated the functionality and
reliability of the experimental setting with respect to the
convection, appropriate sample recovery and absence of
trapped air. Therefore, the upper chamber was replaced by
a chamber with a top made of acrylic glass instead of
Teflon to monitor the processes within the unit. After fill-
ing the lower chamber with buffer the dialysis membrane
was placed on this chamber and the dialysis unit was
closed by attaching the second chamber. The complete
and air bubble free filling of the chamber by smooth neg-
ative pressure was visually controlled. To check whether
there was sufficient convection for a homogenous distri-
bution of the analyzed compounds in the plasma and
whether replacement of the sample volume was readily
achieved, buffer in the reservoir was stained with a green
dye. Then sampling was performed as described above.
The appropriate moment for closing the valve was defined
as the point of time where no visible flow of stained buffer
into the chamber could be observed. It was also deter-
mined if any air bubbles gained access through the sam-
pling aperture during sampling or after removing the
pipette. Control experiments with the dye verified that the
sample was not adulterated during the process of sam-
pling and synchronous replacement of the sample volume
with fresh solution. The degree of convection was control-
led by following the distribution of the green dye into the
clear buffer after sampling. A visually homogenous solu-
tion was obtained within a few minutes under experimen-
tal conditions. Accurate and reproducible sample volume
was assured by weighing ten replicates of samples drawn
under experimental conditions. Parameters for accuracyRespiratory Research 2005, 6:21 http://respiratory-research.com/content/6/1/21
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and reproducibility were within the specifications of the
manufacture of the used pipettor.
For the dialysis experiments a 5 g aliquot of pre-warmed
human lung homogenate (37°C) was filled into one
chamber. 500 µg BDP ex valve was applied to the homoge-
nate employing a dosing device (designed by our working
group, Figure 1) that was composed of a fitting for the
MDI, the tested MDI, and a glass tube to assure reproduc-
ible dosing conditions. Time in which the particle cloud
was allowed to sediment was kept constant. The lung
homogenate was stirred briefly for a fixed period of time.
Subsequently, a dialysis membrane (Spectra/Por™ 6,
MWCO 2000, Spectrum Laboratories, Rancho
Dominguez, USA) was placed on the homogenate, the
dialysis unit was closed by attaching the second chamber.
The second chamber was filled with plasma of 37°C.
Therefore, the valve connecting the dialysis unit to the
plasma reservoir was opened and the dialysis unit was
filled with plasma by producing a mild negative pressure
using a pipette bulb. Afterwards the valve was closed
again. The whole appliance was free of trapped air. The
dialysis unit was incubated at 37°C for 6 hours (Incuba-
tor, Memmert, Schwabach, Germany). For sampling the
aperture on the top of the unit was opened and samples
were drawn using an Eppendorf™ pipette, pipette tips of
which were tightly fitting to the sampling aperture. Sam-
ples of 0.5 mL were drawn. Therefore, the valve connect-
ing the dialysis unit to the reservoir was opened
synchronously to sample drawing. Replacement of the
sample volume with fresh pre-warmed plasma occurred
due to negative pressure produced by the pipette. The
appropriate moment for closing the valve was determined
in control experiments. Samples were stored at -20°C
until further analysis. To determine the BDP dose that was
actually applied to the homogenate by the respective aer-
osol one dialysis chamber was filled with 5 ml of Krebs-
Ringer-HEPES buffer (pH = 7.4) containing 150 µg FP as
internal standard instead of homogenate. Dosing was per-
formed analogous to the dialysis experiments and the
BDP concentration in buffer was analyzed.
Analysis of drug concentrations in dialysis samples
Samples of the dialysis experiments were mixed with 50
µL internal standard solution (3 µg/mL FP in methanol)
and extracted twice with 2 ml diethylether for 20 min
Schematic illustration of the dialysis experiments Figure 1
Schematic illustration of the dialysis experiments. [1] 500 µg BDP ex-valve is applied to human lung homogenate. [2] Dialysis 
membrane is placed on homogenate, the dialysis unit is closed by attaching the second chamber, and the second chamber is 
filled with human plasma. [3] Sampling aperture is closed and the dialysis unit is incubated by 37°C. [4] Sample of 500 µl is 
drawn and the volume is replaced with fresh plasma.
Human lung homogenate
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MDI
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tube
Aerosol
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human plasma
Plasma containing chamber
Pipette
bulb
Sampling aperture
1 2
Closure
Valve
(closed) EppendorfTM pipette
34Respiratory Research 2005, 6:21 http://respiratory-research.com/content/6/1/21
Page 5 of 13
(page number not for citation purposes)
using a roller mixer, followed by centrifugation at 3000
rpm (Labofuge II, Heraeus-Christ GmbH, Osterode am
Harz, Germany) for 5 min. The combined organic phases
were evaporated to dryness under a gentle stream of nitro-
gen at 25°C. The resulting residue was reconstituted in 0.2
mL methanol and analyzed by liquid chromatography
using a Waters HPLC (Milford, USA) consisting of a 1525
binary pump, a 717plus autosampler and 2487 dual
wavelength absorbance detector. Data collection and inte-
gration were accomplished using Breeze™ software ver-
sion 3.30. Analysis was performed on a Symmetry C18
column (150 × 4.6 mm I.D., 5 µm particle size, Waters,
USA). Typically, 20 µL of sample were injected, a flow rate
of 1 mL/min was used, and detection wavelength was set
to 254 nm. Mobile phase consisted of water containing
0.2 % (v/v) acetic acid (A) and acetonitrile (B). The gradi-
ent elution started at 62 % eluent A, decreasing nonline-
arly to 53 % A by 22 min and finally decreasing linearly to
28 % eluent A by 18 min. The lower limit of quantifica-
tion of the assay was 20 ng/mL for all glucocorticoids.
Calculation of the fraction of applied dose determined in 
plasma
The amount of the parent compound BDP and its metab-
olites 17-BMP (active metabolite), 21-BMP and beclom-
ethasone that were distributed from the lung tissue into
plasma were determined and calculated as percentage of
the applied dose. Amount Ai of drug related to the parent
compound found in whole plasma at i-th sample was cal-
culated by the following equations:
(1) VP = r2• π  • h
ci Concentration of the compound at the i-th sample [m/
V]
h Inner height of the plasma containing chamber
MW Molecular weight of the compound
r Inner radius of the plasma containing chamber
VP Calculated volume of plasma in the dialysis unit
On basis of the calculated amount Ai the release of the
drug into plasma Di at the i-th sample can be expressed as
percentage of applied dose using equation (3) or (4):
Aj-1 Amount of drug related to the parent compound
found in whole plasma at the (j-1)-th sample
Dapplied  Actually applied dose to the human lung
homogenate
Human lung perfusion experiments
The lobe preparations were perfused extracorporally for
about 60 min as described previously [14,15]. Immedi-
ately after lung resection, the pulmonary arteries were can-
nulated and the bronchus was connected to a bronchial
tube. After the lung was rinsed through the arteries with
0.5 L of perfusion buffer (85 mM NaCl, 3.5 mM KCl, 2.5
mM CaCl2 × 2 H2O, 1.18 mM MgCl2 × 6 H2O, 2.5 mM
KH2PO4, 20 mM NaHCO3, 5.5 mM glucose, 5 % bovine
serum albumin and 2 % dextran; 100 µl of a stock solu-
tion containing 10,000 IU penicilline and 10,000 µg/mL
streptomycine in 0.9% NaCl were added to 1 L perfusion
buffer and pH was adjusted to 7.4 by addition of 10%
NaHCO3), it was placed within the perfusion apparatus in
a tempered water bath (37°C) and ventilated using a res-
pirator (Engström Erica 2; Engström Elektromedizin
GmbH, München, Germany) with air (Figure 2). The per-
fusion buffer was pumped from a reservoir through a heat
exchanger, an oxigenator, and a bubble trap and was
delivered through a valve into one to three segmental
arteries. After leaving the opened vein, perfusate flowed
back to the reservoir, which was held at 37°C.
During lung perfusion, pH, pO2, pCO2, K+, and Na+ in the
perfusate were monitored continuously with an Esch-
weiler System 2000-D03 (L. Eschweiler & Co., Kiel, Ger-
many) and registered via a computer system. By addition
of CO2 using a conventional oxigenator, perfusate pH was
maintained within the physiological range of about 7.4.
Lung preparations were weighed before and after per-
fusion to check for oedema formation during perfusion.
After ventilation and perfusion were established the sys-
tem was equilibrated for 5 min, and a 5 mL sample (blank
sample) was drawn before administration of the glucocor-
ticoid. Dosing was performed using a glass spacer (con-
structed by our group) that was placed between the
respirator and the ventilated lung tissue. During applica-
tion the tidal volume was increased 1.5-fold in compari-
son to the volume during perfusion. The dose applied
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exvalve was 500 µg BDP for each MDI. Samples of 5 mL
were drawn from the main venous output and the sample
volume was replaced with fresh perfusion buffer. Samples
were immediately frozen and transported on dry ice, and
stored at -20°C until further analysis. In order to calculate
the fraction of dose reaching the human lung lobe the
spacer and all fittings were rinsed quantitatively and ana-
lyzed for BDP. The fraction of BDP that was determined in
the spacer and connecting fittings was subtracted from the
dose of 500 µg applied ex valve. The amount of the parent
compound BDP and its metabolites 17-BMP (active
metabolite), 21-BMP and beclomethasone that were dis-
tributed from the lung tissue into perfusion fluid were
determined and calculated as percentage of the applied
dose analogous to the dialysis experiments.
Analysis of drug concentrations in perfusion samples
Perfusion samples of 1 mL were mixed with 25 µl internal
standard solution (300 ng/mL FP in methanol). Gluco-
corticoids were extracted twice with 3 mL diethylether for
20 min using a roller mixer, followed by centrifugation at
3000 rpm (Labofuge II, Heraeus-Christ GmbH, Osterode
am Harz, Germany) for 5 min. The organic layers were
evaporated to dryness under a gentle stream of nitrogen at
25°C. The residue was reconstituted in 50 µl methanol
and analyzed by HPLC – MS/MS using an Agilent 1100
HPLC system (Agilent Technologies, Waldbronn, Ger-
many) consisting of a binary pump, a vacuum degasser, a
temperature-controlled autosampler and a variable wave-
length absorbance detector coupled with an Agilent LC/
MSD Trap SL mass sensitive detector. An ESI interface was
used in the positive ionization mode. Data collection and
integration were accomplished using ChemStation-for-
LC-3D™ and LC/MSD-Trap™ version 4.2 software. Analy-
sis was performed on a Symmetry C18 column (150 × 4.6
mm I.D., 5 µm particle size, Waters, USA). The mobile
phase was a mixture of water containing 0.1 % (v/v) for-
mic acid (A) and acetonitrile (B), the flow rate was 0.6
mL/min. A gradient elution started at 50 % eluent B,
increasing linearly to 65 % B by 8 min and then increasing
linearly to 80 % B by 8 min. A total sample volume of 25
µL was injected. The mass spectrometer was operated in
selective reaction monitoring observing the transitions
from 465 m/z to 355 m/z, 501 m/z to 313 m/z, and 521
m/z to 411 m/z for 17-BMP, FP (internal standard) and
BDP, respectively. The lower limit of quantification of the
assay was 400 pg/mL for BDP and 17-BMP.
Schematic illustration of the experimental human lung reperfusion setting Figure 2
Schematic illustration of the experimental human lung reperfusion setting.
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Particle topology and dissolution of drug crystals in human 
bronchial fluid visualized by scanning electron microscopy 
(SEM)
Beclomethasone dipropionate (BDP) from different
devices was either directly applied on regular glass micro-
scopy slides or on microscopy slides with incubation slots
of 15 × 2 mm (Karl Roth GmbH, Karlsruhe, Germany)
containing human bronchial fluid. For application of
BDP the glass microscopy slide was placed in a plastic
spacer of about 900 cm3. The aerosol device was actuated
and the glucocorticoid particles were allowed to alight on
the glass slide. Number and distribution of BDP particles
was visually controlled by light microscopy (ECLIPSE
TS100, Nikon, Düsseldorf, Germany). After BDP applica-
tion onto human bronchial fluid the glass microscopy
slide was sealed with silicone paste and a cover slide and
incubated at 37°C for one hour. Thereafter the cover slide
was removed and the fluid was evaporated under a gentle
stream of nitrogen. Subsequently the slide was carefully
washed twice with 50 µL purified water to remove bron-
chial fluid proteins. The water was evaporated under a
stream of nitrogen.
A Zeiss DSM 962 scanning electron microscope (Carl
Zeiss, Oberkochen, Germany) was used to obtain the SEM
photographs. The samples mounted on the glass micros-
copy slides were coated with palladium/coal for 3 min
using a Baltec SCD 005 sputter-coater in an argon atmos-
phere (45 Pa and 50 mA).
Results
Lung tissue-plasma distribution of HFA-BDP determined in 
a dialysis model
The time course of distribution of two different HFA-BDP
formulations from human lung tissue into human plasma
was initially determined using a simple dialysis model.
Therefore, equal doses of 500 µg BDP (2 × 250 µg Sanas-
thmax®/Becloforte™ and 5 × 100 µg Ventolair®/Qvar™) ex
valve  were applied to each 4.8 mL human lung tissue
homogenate (Figure 1). The mean total dose that was
actually deposited in this dialysis chamber was analyzed
by HPLC and calculated to be 152.8 ± 15.4 µg for Sanas-
thmax®/Becloforte™ and 60.6 ± 1.5 µg for Ventolair®/
Qvar™. Subsequently the distribution of BDP and its
metabolites from lung tissue into the second chamber
filled with 9.5 mL human plasma was monitored over 6
hours.
The time course of HFA-BDP distribution in to the plasma
chamber was different for the two formulations (Figure
3). After application of Ventolair®/Qvar™ about 14 % of
the applied dose was delivered into plasma after one hour.
After 6 hours about 65 % of BDP and metabolites were
determined in the plasma compartment. In contrast, after
one hour only about 8 % of the total dose of Sanasth-
max®/Becloforte™ was distributed into plasma. After 6
hours 30 % of Sanasthmax®/Becloforte™ were found in
plasma (Figure 3 A).
Time course of distribution of Sanasthmax®/Becloforte™  and Ventolair®/Qvar™ from human lung tissue into human  plasma at 37°C as determined in dialysis experiments Figure 3
Time course of distribution of Sanasthmax®/Becloforte™ 
and Ventolair®/Qvar™ from human lung tissue into human 
plasma at 37°C as determined in dialysis experiments. Con-
centrations of [3 A] sum of beclomethasone dipropionate 
(BDP) and its metabolites, [3 B] BDP and [3 C] beclometha-
sone-17-monopropionate (17-BMP) were analyzed in plasma 
and expressed as percentage of the total dose applied to the 
lung tissue. Each data point represents the mean and mean 
deviation of the mean of three independent experiments.
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When the time course of delivery into plasma was
regarded separately for BDP and 17-BMP, respectively, the
clear differences between the two formulations were con-
firmed. After 30 min of incubation the plasma concentra-
tion of BDP delivered from Ventolair®/Qvar™ was twice as
high as that of BDP delivered from Sanasthmax®/
Becloforte™ (Figure 3 B). This difference became even
more pronounced after 6 hours of incubation when the
BDP concentration from Sanasthmax®/Becloforte™
decreased while it remained constant after application of
BDP from Ventolair®/Qvar™. Up to 10 % of the applied
dose of Ventolair®/Qvar™ were released unmetabolized as
BDP into plasma while only about up to 6 % of the total
dose Sanasthmax®/Becloforte™ were released
unmetabolized.
The release of the active metabolite 17-BMP into plasma
steadily increased during incubation (Figure 3 C). After 6
hours about 50 % of the total applied dose of Ventolair®/
Qvar™, but only about 25 % of Sanasthmax®/Becloforte™
was distributed into plasma.
Pulmonary absorption of HFA-BDP in a human lung 
perfusion model
A human lung perfusion model was employed to deter-
mine whether the differences of the distribution kinetics
between the two BDP formulations were also present in a
more physiological model. Lung lobes of cancer patients
were extracorporally ventilated and reperfused in a closed
system at 37°C directly after resection. BDP aerosols were
applied via a glass spacer after increasing the respiration
volume to the 1.5 fold of the basal volume. Again equal ex
valve doses of 500 µg HFA-BDP were administered, 2 ×
250 µg of Sanasthmax®/Becloforte™ and 5 × 100 µg of
Ventolair®/Qvar™. After rinsing the glass spacer and all
connecting tubes the fraction of BDP that adhered to
those materials was analyzed after each experiment. By
subtracting this amount from the nominal administered
dose we calculated that mean doses of 343 ± 13.3 µg of
Sanasthmax®/Becloforte™ and 392 ± 40.1 µg of Ventolair®/
Qvar™ were deposited in the lung lobes.
Samples of the perfusion buffer were obtained directly
from the main venous vessel of the lobe. Again the time
course of HFA-BDP distribution into the perfusion fluid
was different for the two formulations (Figure 4). The
mean percentage of the applied dose that was delivered
into the perfusion fluid after application of Ventolair®/
Qvar™ was at all time points about twice a high as the dis-
tributed dose of Sanasthmax®/Becloforte™ (Figure 4 A).
After application of Ventolair®/Qvar™ about 0.8 % of the
BDP was immediately detectable in the perfusion fluid
(Figure 4 B). This equals a mean concentration of 1.7 ng/
mL in the perfusion fluid after only 3 min. Die BDP con-
centration then rapidly decreased over 30 min and then
remained stable at a very low level. Though a very low per-
centage of BDP was also detectable in the perfusion fluid
after application of Sanasthmax®/Becloforte™ it did not
change over the incubation period. Only about 0.18 % of
the total dose of BDP was continuously distributed into
the perfusion buffer.
Time course of distribution of Sanasthmax®/Becloforte™  and Ventolair®/Qvar™ from a ventilated human lung prepa- ration into perfusion fluid at 37°C Figure 4
Time course of distribution of Sanasthmax®/Becloforte™ 
and Ventolair®/Qvar™ from a ventilated human lung prepa-
ration into perfusion fluid at 37°C. Samples were obtained 
form the main venous vessel of the lung lobe and the drug 
concentration was expressed as percentage of the total dose 
applied to the lung lobe. [4 A] Sum of beclomethasone dipro-
pionate (BDP) and its metabolites, [4 B] BDP and [4 C] 
beclomethasone-17-monopropionate (17-BMP). Each data 
point represents the mean and mean deviation of the mean 
of three independent experiments.
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Analysis of 17-BMP concentrations after aerosol adminis-
tration confirmed the differences in distribution observed
between the two formulations. Over the whole incuba-
tion period about twice as high 17-BMP concentrations
were observed after application of Ventolair®/Qvar™ com-
pared with Sanasthmax®/Becloforte™ (Figure 4 C). While
between 1.5 and 2 % of 17-BMP of the total applied dose
from Ventolair®/Qvar™ were found, only between 0.5 and
1 % of 17-BMP were detected in the perfusion fluid after
application of Sanasthmax®/Becloforte™. Interestingly, the
active metabolite 17-BMP was already detectable in the
perfusion fluid 2–3 min after application of both aerosols.
As expected, the concentration of 17-BMP in the perfusion
fluid gradually increased over the incubation time. This is
consistent with a slow dissolution process of drug crystals.
Particle topology and dissolution of drug crystals in human 
bronchial fluid visualized by scanning electron microscopy 
(SEM)
Beclomethasone dipropionate (BDP) particles delivered
by pressurized metered dose inhalers (MDI) with
hydrofluorocarbon (HFA) propellant (Sanasthmax®/
Becloforte™ and Ventolair®/Qvar™) were analyzed by
SEM. To visualize the particle topology the devices were
actuated and the particles were allowed to alight directly
on regular glass microscopy slides. Representative HFA-
BDP particles delivered by Sanasthmax®/Becloforte™ were
about 2 µm (Figure 5, I a). BDP delivered by Sanasthmax®/
Becloforte™ is solved in the HFA propellant. The particle
size visualized by SEM is consistent with the published
mass mean median aerodynamic diameter of about 2.6
µm [17]. These BDP particles showed a unique structure,
they appeared round and highly porous. Obviously, a big
surface area of the sponge-like form was generated by a
rapid evaporation of the propellant.
To get an impression of the process of dissolution of these
BDP particles in human bronchial fluid the Sanasthmax®/
Becloforte™ device was actuated and the glucocorticoid
particles were allowed to alight on microscopy slides with
incubation slots. Each incubation slot accommodated
about 40–50 individual BDP particles as controlled under
a light microscope. The incubation slot was filled with
200 µL human bronchial fluid, sealed and incubated for
one hour at 37°C. After this incubation time the SEM pic-
ture revealed that the form of the particles changed signif-
icantly. While the particles were still around 2 µm they
now resembled solid cubic crystals (Figure 5, I b).
Obviously, BDP particles re-crystallized after they came in
contact with the bronchial fluid and formed crystals with
a thermodynamically preferred smaller surface area.
BDP delivered by Ventolair®/Qvar™ is solved in the HFA
propellant. BDP particles delivered by Ventolair®/Qvar™
are smaller than those delivered by the Sanasthmax®/
Becloforte™ device. Representative particles shown (Figure
5, II a) are about 1 µm which is in agreement with the
published mass mean median aerodynamic diameter of
about 1.1 µm [18,19]. Again, these particles showed a typ-
ical structure, they appeared round and not porous, but
droplet-like.
This BDP formulation was also incubated with human
bronchial fluid for one hour at 37°C. The form of the par-
ticles changed to solid cubic crystals as seen with the other
HFA-BDP formulation. However, most of the particles
were now clearly smaller than 1 µm and the edges of the
cubes appeared rounded. Obviously, the crystals were in a
more advanced state of dissolution in bronchial fluid
(Figure 5, II b).
For comparison, we show a SEM image of BDP formu-
lated as Sanasthmax®/Becloforte™ delivered from a MDI
with CFC propellant and applied directly on a glass micro-
scope slide (Figure 6). The particles were typically crystal-
like, clearly bigger and less homogeneous than the parti-
cles delivered from any of the HFA driven aerosols. The
size of these representative crystals is again consistent with
the published mass mean median aerodynamic diameter
of about 3.5 to 4.0 µm [18,19].
Discussion
In the present study we successfully demonstrated that the
intial distribution of beclomethasone dipropionate
(BDP) from lung tissue into extrapulmonary circulation
can be assessed employing a human lung perfusion
model. Therefore, we applied BDP delivered by two differ-
ent commercially available HFA-propelled aerosols
(Sanasthmax®/Becloforte™ and Ventolair®/Qvar™) into a
reperfused and ventilated lung lobe and measured the rate
and extend of pulmonary absorption. We succeeded to
explain kinetic differences we observed between the two
aerosols with unique particle topology and divergent dis-
solution behaviour in human bronchial fluid.
Prolonged retention times in the therapeutic target tissue
lung are a highly favourable characteristic of inhaled glu-
cocorticoids and contribute to an improved therapeutic
index. This principle was obviously taken into considera-
tion for newly developed glucocorticoids for pulmonary
application. All inhaled glucocorticoids of the latest gen-
eration reveal high lipophilicity and high tissue binding
affinity. As additional mechanisms of tissue retention the
formation of intracellular conjugates was reported for
budesonide and ciclesonide's active metabolite [20,21].
Compound properties such as dissolution of drug crystals
[22,23] and the glucocorticoids' tissue binding affinity
[24] might be separately elucidated in vitro. The general
differences determined between various glucocorticoids inRespiratory Research 2005, 6:21 http://respiratory-research.com/content/6/1/21
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vitro  roughly agree with relation between tissue and
plasma concentrations of these compounds at a certain
time after inhalation in patients [9-11]. To elucidate the
kinetics of pulmonary absorption plasma samples of
patients or volunteers might be collected over a certain
time interval after inhalation [12]. However, with this
approach it cannot be excluded that the concentration of
active drug being absorbed from the lungs is slightly
underestimated due to partial hepatic metabolism. If glu-
cocorticoids with a significant oral bioavailability are
investigated gut absorption after swallowing has to be dis-
cerned from pulmonary absorption.
We evaluated novel approaches to elucidate pulmonary
absorption of an inhaled glucocorticoid in vitro. There-
fore, we compared BDP formulations delivered from two
different commercially available pressurized metered
dose inhaler devices. With both experimental settings, the
dialysis experiments and the human lung perfusion
model, we had precise information about the dose
Scanning electron microscopy image of BDP particles either as delivered directly from the device on a glass slide [I a, II a] or in  the stage of partial dissolution after incubation for one hour at 37°C with human bronchial fluid [I b, II b] Figure 5
Scanning electron microscopy image of BDP particles either as delivered directly from the device on a glass slide [I a, II a] or in 
the stage of partial dissolution after incubation for one hour at 37°C with human bronchial fluid [I b, II b]. [I a] BDP particle as 
delivered from the Sanasthmax®/Becloforte™ formulation propelled by hydrofluoroalkane (HFA), [I b] HFA-BDP particles 
delivered from the Sanasthmax®/Becloforte™ formulation after incubation with human bronchial fluid at 37°C for one hour, [II 
a] HFA-BDP particles as delivered from the Ventolair®/Qvar™ formulation, [II b] HFA-BDP particles delivered from the 
Ventolair®/Qvar™ formulation after incubation with human bronchial fluid at 37°C for one hour.
X20000 2µm                          15kV      6mm
#240502  BDP Sana/CR
I a
X20000 2µm                          15kV      7mm
#240514 BDP Sana/BS 1H
I b
X20000 2µm                          15kV      6mm
#240506  BDP Vento/CR
II a
X20000 2µm                          15kV      6mm
#240509  BDP Vento/BS 1H
II bRespiratory Research 2005, 6:21 http://respiratory-research.com/content/6/1/21
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applied to the lung tissue. With both models were able to
study the combined processes of drug dissolution, activa-
tion to the active metabolite beclomethasone-17-mono-
propionate (17-BMP) and the distribution of BDP and 17-
BMP from lung tissue into plasma or perfusion fluid,
respectively.
We used the newly developed dialysis model to monitor
the kinetics of drug diffusion over six hours. During this
time we observed constant drug transfer into plasma and
continuous generation of the active BDP metabolite. The
latter suggests that the non-specific esterases responsible
for pro-drug activation were functional within the chosen
time interval. We ventilated and reperfused the resected
human lung lobe over about one hour to be as close as
possible to physiological conditions and avoid problems
such as oedema formation that might be associated with
prolonged perfusion times. The time interval of one hour
is consistent with the time to reach maximal plasma levels
(tmax) of BDP and its ester metabolites after inhalation of
HFA-BDP in various clinical studies [25-28]. Since these
peak plasma levels were observed between 0.34 [28] and
0.9 hours [25] the reperfusion time of one hour appeared
acceptable for our experiments. In our human lung reper-
fusion model we observed a continuous generation of 17-
BDP and rapid transfer of BDP and 17-BMP into the per-
fusion fluid. Though the absorption rates of BDP and 17-
BMP were quantitatively higher in the dialysis model, they
were qualitatively consistent in both models.
Unexpectedly, we observed differences between the two
HFA aerosol formulations Sanasthmax®/Becloforte™ and
Ventolair®/Qvar™ in both the dialysis and the lung reper-
fusion setting. The mean release of BDP and 17-BMP from
lung tissue into plasma or perfusion fluid was about twice
as high after application of Ventolair®/Qvar™ compared
with Sanasthmax®/Becloforte™.
In contrast to the unanticipated results of our absorption
experiments with two HFA formulations, differences in
pulmonary absorption after administration of CFC-BDP
compared to HFA-BDP would have been expected based
on the results of clinical studies. After inhalation of HFA-
propelled BDP higher lung deposition rates were achieved
and higher plasma concentrations of 17-BMP were
observed in adults [25,26] and children [28]. The ration-
ale of a higher lung deposition and thus the need for
lower doses of HFA-BDP in clinical settings is the differ-
ence in fine particle mass compared to the CFC-BDP [29].
The smaller particles delivered by HFA formulations result
in a higher respirable fraction and improved deposition of
particles especially in smaller airways [30]. The higher
lung deposition of smaller drug particles correlates with a
shorter the time to maximum plasma concentration (tmax)
of 17-BMP or beclomethasone esters, respectively, after
inhalation of HFA-BDP compared to CFC-BDP [25,26].
The median tmax of 17-BMP after inhalation of CFC-BDP
was not significantly altered when activated charcoal was
co-administered and thus gut absorption was prevented
[17,31]. A plausible explanation for the delayed tmax of 17-
BMP after inhalation of CFC-BDP is the particle size as it
should be expected that bigger drug crystals dissolve more
slowly. HFA-BDP with its smaller particles exhibited a
faster and more efficient systemic drug delivery [26].
Based on the comprehension of the interrelation of aero-
sol particle size and rate of pulmonary absorption we sus-
pected that the different time courses of distribution into
extrapulmonary compartments we observed were due to
different particle sizes of HFA-BDP formulated as Sanasth-
max®/Becloforte™ or Ventolair®/Qvar™, respectively. Scan-
ning electron microscopic experiments illustratively
confirmed this postulate. Particles of BDP delivered by
Ventolair®/Qvar™ were significantly smaller and displayed
faster dissolution in human bronchial fluid compared to
particles delivered by Sanasthmax®/Becloforte™. Addition-
ally, for the first time we provide evidence that BDP parti-
cles delivered by HFA-propelled aerosols are subjected to
a re-crystallization process once they come in contact with
the bronchial fluid. Obviously, the particles as delivered
from the device dissolve rapidly due to their large surface
area. Subsequently, locally oversaturated solutions tend
to crystallize and crystals with a thermodynamically pre-
ferred smaller surface area are formed. It seems very likely
that this might also occur in the life human lung since the
Scanning electron microscopy image of BDP particles as  delivered from the Sanasthmax®/Becloforte™ formulation  propelled by chlorofluorocarbon (CFC) Figure 6
Scanning electron microscopy image of BDP particles as 
delivered from the Sanasthmax®/Becloforte™ formulation 
propelled by chlorofluorocarbon (CFC).
X20000 2µm                        15kV      6mm
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volume of bronchial fluid is very limited. This re-crystalli-
zation of particles with high surface area to solid cubic
particles with smaller surface area would be a highly
desired effect as it slows down the further dissolution and
therefore prolongs the pulmonary residence time.
The notion that BDP delivered by HFA-propelled inhalers
initially rapidly dissolves and then locally re-crystallizes
would also explain the detection of BDP in reperfusion
fluid of the human lung preparation after only 2–3 min.
It seems plausible that a certain amount of dissolved drug
is instantly distributed into extrapulmonary compart-
ments since the human lung has a high inner surface area
and is the organ with the highest blood flow of about 15
L/min/kg [32]. The detection of BDP in the perfusion
fluid is consistent with earlier studies reporting
unchanged BDP in plasma samples of volunteers after
inhalation of BDP [17,31]. Interestingly, an enhanced
pulmonary absorption rate after inhalation of HFA-BDP
compared to CFC-BDP was reported to correspond with
an increased absorption of unchanged BDP [17,33]. In
our human lung perfusion model we also detected higher
levels of BDP in perfusion fluid after application of Ven-
tolair®/Qvar™ with its smaller BDP particles. The fact that
we also detected the active metabolite 17-BMP in the per-
fusion fluid of the extracorporally perfused and ventilated
lung lobe after only 2–3 min allows the conclusion that
the hydrolysis of BDP is an extremely rapid process. This
is in excellent agreement with the results of earlier in vitro
assays with human lung tissue [34]. Hence, the activation
of the pro-drug BDP to 17-BMP is no rate-limiting step
while the dissolution of drug crystals determines the rate
of pulmonary absorption.
To summarize, we employed two different models to
monitor the distribution kinetics of two HFA-propelled
BDP aerosols from human lung tissue into extra-pulmo-
nary compartments. With both the dialysis setting as well
with the human lung perfusion model we detected signif-
icant differences between the two BDP formulations. The
HFA-BDP formulated as Ventolair®/Qvar™ displayed a
rapid release from lung tissue while Sanasthmax®/
Becloforte™ exhibited a prolonged residence time in tis-
sue. We succeeded to explain the observed differences in
lung tissue residence time on the basis of the particle size
and dissolution behaviour in human bronchial fluid. We
conclude that though the ultrafine particles of Ventolair®/
Qvar™ are beneficial for high lung deposition [30,35],
they also yield an undesired more rapid systemic drug
delivery. While the differences between Sanasthmax®/
Becloforte™ and Ventolair®/Qvar™ were obvious in both
the dialysis and lung perfusion experiments, the latter
allowed to record time courses of pro-drug activation and
distribution that were more consistent with results of
comparable clinical trials. Though it is not clear whether
the kinetic differences observed between Sanasthmax®/
Becloforte™ and Ventolair®/Qvar™ might be of clinical
relevance the detection of divergent absorption kinetics
confirm the functionality and sensitivity of our experi-
mental setting. Thus, the extracorporally perfused and
ventilated human lung is a highly valuable physiological
model to explore the comparative lung pharmacokinetics
of inhaled drugs.
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